- ICH GCP
- US Clinical Trials Registry
- Search trials
Search clinical trials for: Glycogen Storage Disease Type II
Total 389386 results
-
University of FloridaNational Heart, Lung, and Blood Institute (NHLBI)CompletedPompe DiseaseUnited States
-
National Cerebral and Cardiovascular CenterMinistry of Health, Labor and Welfare (Japan)TerminatedMyocardial Infarction | Impaired Glucose ToleranceJapan
-
Amicus TherapeuticsTerminated
-
BioMarin PharmaceuticalTerminatedLate-onset Pompe DiseaseUnited States, United Kingdom, Germany, France, Italy, Portugal, Belgium, Netherlands
-
BioMarin PharmaceuticalCompletedPompe DiseaseUnited States, United Kingdom, France, Australia, Germany
-
BioMarin PharmaceuticalTerminatedPompe DiseaseUnited States, United Kingdom, Australia, France, Germany, New Zealand
-
University of FloridaTerminated
-
University Medical Center GroningenUniversity of Oxford; University of the Faroe Islands; Stichting Stofwisselkracht and other collaboratorsCompleted
-
University of FloridaCompletedPompe DiseaseUnited States
-
Rambam Health Care CampusCompletedEnzyme Replacement Therapy in Pompe Disease
-
O & O Alpan LLCUnknownFabry Disease | Niemann-Pick Disease | Gaucher Disease | Pompe Disease | Lysosomal Storage DisordersUnited States
-
Fundació Institut de Recerca de l'Hospital de la...Genzyme, a Sanofi CompanyUnknownPompe Disease | Late Onset Pompe DiseaseSpain
-
BioMarin PharmaceuticalTerminatedLate-onset Pompe Patients Untreated or Treated With rhGAASpain, Slovenia, Serbia, Korea, Republic of, Greece, Australia, Singapore, Brazil, Canada, Taiwan, Ireland, Poland, Romania
-
O & O Alpan LLCCompleted
-
National Taiwan University HospitalCompleted
-
Centre Hospitalier de CayenneCompleted
-
Centre Hospitalier de CayenneCompleted
-
Taipei Veterans General Hospital, TaiwanUnknownGlycogen Storage Disease Type IITaiwan
-
National Taiwan University HospitalUnknown
-
University of AarhusUnknownGlycogen Storage Disease Type 2 | Dystrophia MyotonicaDenmark
-
Genzyme, a Sanofi CompanyTerminatedGlycogenosis 2 | Glycogen Storage Disease Type II (GSD II) | Acid Maltase Deficiency | Pompe Disease (Infantile-Onset)United States, Taiwan, Germany
-
Genzyme, a Sanofi CompanyTerminatedPompe DiseaseUnited States
-
John MitchellCompletedGlycogen Storage Disease Type III | Glycogen Storage Disease Type IA | Glycogen Storage Disease Type IB | Glycogen Storage Disease Type 0Canada
-
Royal Brompton & Harefield NHS Foundation TrustGenzyme, a Sanofi CompanyUnknownPompe's Disease
-
Genzyme, a Sanofi CompanyCompleted
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type IIUnited States, France, Netherlands
-
Genzyme, a Sanofi CompanyCompletedPompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2United States, France, Netherlands
-
Columbia UniversityWithdrawnGlycogen Storage Disease Type IIUnited States
-
National Taiwan University HospitalUnknown
-
Genzyme, a Sanofi CompanyCompletedGlycogenesis 2 Acid Maltase Deficiency | Pompe Disease (Late-Onset) | Glycogen Storage Disease Type II (GSD II)United States, Netherlands, United Kingdom, Germany
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe DiseaseUnited States
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Pompe DiseaseUnited States
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II (GSD-II) | Pompe Disease (Late-Onset) | Glycogenesis Type II | Acid Maltase Deficiency (AMD)United States, France, Canada, Netherlands, Australia
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II (GSD-II) | Pompe Disease | Glycogenesis 2 Acid Maltase DeficiencyUnited States, Canada, Australia
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type IIUnited States, France, Germany, Israel, Italy, Netherlands, Taiwan
-
Genzyme, a Sanofi CompanyCompletedPompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2Netherlands
-
Genzyme, a Sanofi CompanyApproved for marketingGlycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe Disease (Late-Onset)United States
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Glycogenosis 2United States
-
Genzyme, a Sanofi CompanyCompletedGlycogenesis 2 Acid Maltase Deficiency | Pompe Disease (Late-Onset) | Glycogen Storage Disease Type II (GSD II)France
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe DiseaseUnited States
-
Genzyme, a Sanofi CompanyCompletedPompe Disease Late-Onset | Glycogen Storage Disease Type II GSD IIUnited States
-
Genzyme, a Sanofi CompanyCompletedPompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2France
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Pompe Disease Infantile-OnsetUnited States, France, South Africa
-
Genzyme, a Sanofi CompanyApproved for marketingGlycogen Storage Disease Type II | Glycogenosis 2
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe DiseaseUnited States, Israel, France, United Kingdom
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type IIUnited States, Taiwan, Israel, United Kingdom, France
-
National Taiwan University HospitalUnknown
-
Fundació Institut de Recerca de l'Hospital de la...Genzyme, a Sanofi CompanyUnknown
-
University of WashingtonSanofiCompleted